SARS-CoV-2 Vaccines: Status Report

By F. Amanat, F. Krammer. Immunity, 2020

1,041 citations recorded by the source corpus.

SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccines against rapidly emerging viruses. Importantly, SARS-CoV-2 vaccines will be essential to reducing morbidity and mortality if the virus establishes itself in the population.

Subfields: Infectious Diseases, Neurology

View Paper: https://www.semanticscholar.org/paper/e621863e2383f1b5b4f4bc104d89bacdd2295855

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Na-Na Zhang
2. Xiao-Feng Li
3. Yongqiang Deng
4. Hui Zhao
5. Mei-Yue Wang
6. Yi-Jiao Huang
7. Guan Yang
8. Weijing Huang

Citations in the corpus

• A Thermostable mRNA Vaccine against COVID-19 (2020, positive): “The full-length S protein, S1, and RBD are capable of inducing highly potent neutralizing antibodies and T cell-mediated immunity and, therefore, have been widely selected as promising targets for coronavirus vaccine development (Amanat and Krammer, 2020).”
• Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity (2020, neutral): “Thus, most COVID-19 vaccine efforts focus on the elicitation of neutralizing antibodies (Amanat and Krammer, 2020; Corey et al., 2020; Thanh Le et al., 2020), with additional interest in elicitation of CD4 or CD8 T cells (Corbett et al.”
• Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals (2020, neutral): “Vaccines against SARS-CoV-2 are just beginning development (Amanat and Krammer, 2020; Thanh Le et al., 2020).”
• Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 (2020, positive): “However, in the past two decades, three highly pathogenic human betacoronaviruses have emerged from zoonotic events (Amanat and Krammer, 2020).”
• Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment (2020, background): “Remdesivir has been promised antiviral drug against RNA viruses, including SARS/MERS, in cultured cell, mice and nonhuman primate model (Sheahan et al., 2017).”
• SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development (2020, background): “It is urgent to develop effective and safe vaccines to control the new occurrence of COVID-19 and to reduce SARS-CoV-2infection-related morbidity and mortality (Amanat and Krammer, 2020).”